Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
What is Hunan Warrant Pharmaceutical Co EV-to-EBIT?
Hunan Warrant Pharmaceutical CoSHSE:688799 -2.42%80 EV-to-EBIT is 28.35 as of Sep. 09, 2026, which is 73% above its 10-year median of 16.40. GuruFocus rates SHSE:688799 with a GF Score™ of 80/100 and a GF Value™ of ¥34.70 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 682 Drug Manufacturers companies, Hunan Warrant Pharmaceutical Co ranks worse than 71.41% on this metric.
Hunan Warrant Pharmaceutical Co (SHSE:688799) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Hunan Warrant Pharmaceutical Co's Enterprise Value for the quarter that ended in Jun. 2026 was ¥6,482 Mil.
Hunan Warrant Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥243 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hunan Warrant Pharmaceutical Co EV-to-EBIT Related Terms
Hunan Warrant Pharmaceutical Co EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Hunan Warrant Pharmaceutical Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Hunan Warrant Pharmaceutical Co EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Hunan Warrant Pharmaceutical Co's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Hunan Warrant Pharmaceutical Co's EV-to-EBIT falls into.
Hunan Warrant Pharmaceutical Co's current Enterprise Value is ¥6,892 Mil.
Hunan Warrant Pharmaceutical Co's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥243 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Hunan Warrant Pharmaceutical Co (SHSE:688799) has a EV-to-EBIT of 28.35 as of Sep. 09, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Hunan Warrant Pharmaceutical Co and its competitors. This is 73% above median its historical median of 16.40. Over the past decade, Hunan Warrant Pharmaceutical Co's EV-to-EBIT has ranged from 11.61 to 76.78. According to the industry distribution chart, Hunan Warrant Pharmaceutical Co ranks #487 out of 682 companies in the Drug Manufacturers industry, placing it in the top 71.4%.
Is Hunan Warrant Pharmaceutical Co's EV-to-EBIT too high?
Hunan Warrant Pharmaceutical Co's current EV-to-EBIT of 28.35 is 73% above median its 10-year median of 16.40. Over the past 10 years, this metric has ranged from a low of 11.61 to a high of 76.78. The Drug Manufacturers industry median EV-to-EBIT is 16.11. Hunan Warrant Pharmaceutical Co's value of 28.35 is 76% above this industry median. Based on the distribution chart, Hunan Warrant Pharmaceutical Co ranks #487 out of 682 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Hunan Warrant Pharmaceutical Co has a GF Score™ of 80/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Hunan Warrant Pharmaceutical Co's EV-to-EBIT compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Hunan Warrant Pharmaceutical Co ranks #487 out of 682 companies for EV-to-EBIT. This places Hunan Warrant Pharmaceutical Co in the lower half of its industry. The industry median EV-to-EBIT is 16.11. Hunan Warrant Pharmaceutical Co's value of 28.35 is 76% above this benchmark. Historically, Hunan Warrant Pharmaceutical Co's own EV-to-EBIT has ranged from 11.61 to 76.78 over the past decade. While the company's 10-year median is 16.40 vs. the industry median of 16.11, Hunan Warrant Pharmaceutical Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 16.11, based on 682 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Hunan Warrant Pharmaceutical Co's current EV-to-EBIT of 28.35 is 76% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Hunan Warrant Pharmaceutical Co and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 16.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Hunan Warrant Pharmaceutical Co's current EV-to-EBIT is 28.35, which is 73% above median its own 10-year median of 16.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hunan Warrant Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Hunan Warrant Pharmaceutical Co (SHSE:688799) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥34.70, compared to a current price of ¥48.41 — trading 39.5% above its estimated fair value. The current EV-to-EBIT is 28.35, which is 73% above median its 10-year median of 16.40 and 76% above the Drug Manufacturers industry median of 16.11. Hunan Warrant Pharmaceutical Co's overall GF Score™ is 80/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Hunan Warrant Pharmaceutical Co (SHSE:688799), the current EV-to-EBIT is 28.35 as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Hunan Warrant Pharmaceutical Co (SHSE:688799) Overvalued in 2026?
Based on GuruFocus' analysis, Hunan Warrant Pharmaceutical Co stock appears to be overvalued.
The current stock price of ¥48.41 is trading 39.5% above its estimated GF Value™ of ¥34.70.
GuruFocus considers Hunan Warrant Pharmaceutical Co to be Significantly Overvalued.
Key valuation signals for SHSE:688799:
EV-to-EBIT: 28.35 (73% above median its 10-year median of 16.40)
GF Value™: ¥34.70 vs. price of ¥48.41 (39.5% above fair value)
Industry Position: 76% above the Drug Manufacturers median (#487 of 682)
No single metric tells the full story. See the SHSE:688799 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Hunan Warrant Pharmaceutical Co Ltd is a pharmaceutical manufacturer. It is engaged in the research and development, production and sales of chemical raw materials, chemical medicine preparations and Chinese medicine preparations.
80GF Score
Get the complete analysis for SHSE:688799
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688799 has been successfully added to your 
